Bedrijfsoverzicht
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology firm dedicated to the development and commercialization of adeno-associated virus-based gene therapies specifically designed for severe monogenic diseases affecting the central nervous system. The company operates within the broader Healthcare sector and functions specifically in the Biotechnology industry, an environment characterized by high regulatory hurdles, significant research expenditures, and potential for transformative medical treatments. According to current market data, the firm carries a market capitalization of $1.29 billion, generates annual revenue of $9.77 million, and employs a workforce of 99 individuals. These financial dimensions indicate that while the company has secured a substantial valuation relative to its current revenue base, it remains in an early-stage operational phase where market capitalization often reflects potential future pipeline value rather than established profitability or cash generation.
Financiële gezondheid
The company reported revenue of $9.77 million over the trailing twelve months, while posting a net income of -$108,995,000 and an EBITDA of -$109,353,000, highlighting a substantial disparity between top-line sales and bottom-line profitability that points to an aggressive cost structure typical of clinical-stage development. This gap between revenue and net income reveals that operating expenses, likely dominated by research and development costs and personnel, significantly outpace current sales, resulting in a net loss that is nearly eleven times the size of the revenue generated. Free cash flow stands at -$56,697,624, indicating that the company is burning cash at a rapid pace, which necessitates a robust capital management strategy to maintain financial flexibility without immediate external funding. The gross margin is listed at 100.0%, suggesting that cost of goods sold is currently negligible or non-existent in the context of the reported figures, likely due to the pre-commercial nature of the products, whereas the operating margin of -516.0% underscores the intensity of overhead costs required to advance the clinical pipeline. The profit margin is recorded at 0.0%, consistent with the net loss position where losses exceed the revenue base. On the liability side, Taysha holds $319.77 million in cash against $70.14 million in debt, creating a net cash position, although the debt-to-equity ratio of 28.41 suggests a highly leveraged structural profile relative to shareholder equity in accounting terms. The current ratio of 12.23 indicates exceptional short-term liquidity, providing ample coverage for immediate obligations despite the high debt-to-equity figure. Finally, the return on equity is -68.5% and the return on assets is -27.4%, metrics that reveal management is currently utilizing the company's capital base to generate losses rather than positive returns, a standard characteristic for biotechnology firms in the clinical trial phase.
Waarderingsbeoordeling
Valuation multiples for the company show a trailing P/E ratio of N/A due to the negative earnings, while the forward P/E is reported at -11.02, implying that the market prices the stock based on anticipated future profitability rather than current performance. The price-to-book ratio is 5.18, indicating that the market values the company at more than five times its book value, which often reflects the intangible value of intellectual property and the potential of the clinical pipeline exceeding the recorded net assets. Alternative valuation metrics such as the price-to-sales ratio of 131.98 and an EV/EBITDA of -9.51 suggest that investors are willing to pay a significant premium per dollar of sales, acknowledging that traditional earnings-based multiples are not applicable in the current loss-making stage. Regarding trading ranges, the 52-week high is $6.02 and the 52-week low is $1.13; without a specific current price to calculate the exact percentage deviation, the stock is positioned within a range of 516% volatility between its recent highs and lows. The beta value of 1.08 indicates that the stock's price volatility is slightly higher than the broader market, meaning it tends to move with greater intensity than the overall index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year stands at 171.3%, demonstrating a rapid expansion in sales, while earnings growth is marked as N/A due to the absence of positive earnings in the prior period. Since earnings growth cannot be calculated against negative or zero profits, the disparity implies that the company is prioritizing revenue expansion through market uptake or sales milestones over immediate profit generation. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available resources are being retained and reinvested directly into research, development, and clinical trials rather than distributed to shareholders. Consequently, the overall growth and income profile is defined by high revenue expansion coupled with zero current income distribution, reflecting a classic growth-stage biotechnology model focused entirely on capitalizing on future product approvals rather than providing current yield.